Show simple item record

Dislipidemija u dijabetes melitusu tip 2

dc.creatorStefanović, Aleksandra
dc.creatorZeljković, Aleksandra
dc.creatorVekić, Jelena
dc.creatorSpasojević-Kalimanovska, Vesna
dc.creatorJelić-Ivanović, Zorana
dc.creatorSpasić, Slavica
dc.date.accessioned2020-05-27T09:06:16Z
dc.date.available2020-05-27T09:06:16Z
dc.date.issued2019
dc.identifier.issn0004-1963
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3560
dc.description.abstractType 2 diabetes mellitus is a chronic high-prevalence metabolic disease, which is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with type 2 diabetes have a high risk for cardiovascular disease (CVD) development and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high density lipoprotein cholesterol (HDL-c) concentrations, and a shift in low-density lipoprotein particles (LDL) distribution toward the small, triglycerides-rich particles, are the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein particles (HDL) also undergo structural and functional changes and, as a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and without any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk.en
dc.description.abstractDijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom, ali i poremećajima u metabolizmu lipida i proteina. Pacijenti sa tipom 2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra ključnim uzročnikom ovog povećanog rizika. Hipertrigliceridemija, snižena koncentracija holesterola u lipoproteinskim česticama visoke gustine (HDL-h) i promena u raspodeli lipoproteinskih čestica niske gustine (LDL) u smeru većeg udela malih čestica, bogatih trigliceridima, predstavljaju najvažnije promene lipidnog profila koje se odnose na dislipidemiju u dijabetesu. Kako je dijabetes stanje kontinuirane blage inflamacije niskog stepena i stalne produkcije slobodnih radikala, HDL lipoproteinske čestice takođe podležu strukturnim i funkcionalnim promenama, usled čega gube svoje ateroprotektivne osobine. Terapija dislipidemije kod pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB.sr
dc.publisherBeograd : Savez farmaceutskih udruženja Srbije
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS//
dc.rightsopenAccess
dc.sourceArhiv za farmaciju
dc.subjectCardiovascular disease risk
dc.subjectDiabetes mellitus type 2
dc.subjectDyslipidemia
dc.subjectdijabetes melitus tip 2
dc.subjectdislipidemija
dc.subjectzik za razvoj kardiovaskularnih bolesti
dc.titleDyslipidemia in type 2 diabetes mellitusen
dc.titleDislipidemija u dijabetes melitusu tip 2sr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractВекић, Јелена; Зељковић, Aлександра; Спасић, Славица; Јелић-Ивановић, Зорана; Стефановић, Aлександра; Спасојевић-Калимановска, Весна; Дислипидемија у дијабетес мелитусу тип 2;
dc.citation.volume69
dc.citation.issue5
dc.citation.spage338
dc.citation.epage348
dc.citation.rankM52
dc.identifier.doi10.5937/arhfarm1905338S
dc.identifier.scopus2-s2.0-85080854356
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/7639/Dyslipidemia_in_type_pub_2019.pdf
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record